|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12345678910111213...2930» |
- Enrollment closed: Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Poudre Valley Health System
Recruiting --> Active, not recruiting
- ||| Trial completion: Dyslipidemia Management in Chinese Post Stroke Patients (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=5000, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Wolman/CESD Natural History Chart Review and Longitudinal Follow-Up (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=4, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Completed Recruiting --> Completed | N=50 --> 4 | Trial primary completion date: Dec 2015 --> May 2014
- ||| trigonellinamide (TRIA-662) / Cortria
Enrollment closed: A Pilot Study to Evaluate the Lipid Effects of TRIA-662 (clinicaltrials.gov) - Aug 11, 2015
P2, N=64, Active, not recruiting, Sponsor: Cortria Corporation
Recruiting --> Completed | N=50 --> 4 | Trial primary completion date: Dec 2015 --> May 2014 Recruiting --> Active, not recruiting
- Trial completion: Bergamot and Cardio-Metabolic Risk Factors (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=160, Completed, Sponsor: University of Palermo
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol (clinicaltrials.gov) - Aug 11, 2015
P1, N=20, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Trial completion, Enrollment change: ECLIPSEIV: An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova (clinicaltrials.gov) - Aug 5, 2015
P1, N=30, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 30
- Trial primary completion date: The Natural History of Infantile Globoid Cell Leukodystrophy (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=6, Completed, Sponsor: Zymenex A/S
Active, not recruiting --> Completed | N=24 --> 30 Trial primary completion date: Jul 2015 --> Jul 2014
- |||||| bococizumab (RN316) / Pfizer
Enrollment open: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Jul 17, 2015
P3, N=300, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jul 2015 --> Jul 2014 Active, not recruiting --> Recruiting
- Trial completion, Trial primary completion date: The Natural History of Infantile Globoid Cell Leukodystrophy (clinicaltrials.gov) - Jul 16, 2015
P=N/A, N=5, Completed, Sponsor: Zymenex A/S
Active, not recruiting --> Recruiting Enrolling by invitation --> Completed | Trial primary completion date: Sep 2013 --> Jul 2015
- || rosuvastatin / Generic mfg.
Trial completion, Enrollment change: HYDRA: A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Jul 16, 2015
P3, N=20, Completed, Sponsor: AstraZeneca
Enrolling by invitation --> Completed | Trial primary completion date: Sep 2013 --> Jul 2015 Active, not recruiting --> Completed | N=25 --> 20
- |||| bococizumab (RN316) / Pfizer
Trial primary completion date: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Jul 13, 2015
P3, N=690, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | N=25 --> 20 Trial primary completion date: Jun 2015 --> Jun 2016
- rosuvastatin / Generic mfg.
Trial completion: Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia (clinicaltrials.gov) - Jul 8, 2015
P4, N=223, Completed, Sponsor: Dong-A ST Co., Ltd.
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Completed
- Trial primary completion date: Effects of Amino Acids on Regional Lipid Metabolism (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=50, Recruiting, Sponsor: University of Arkansas
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Aug 2016
- | Galafold (migalastat) / Amicus
Trial primary completion date: Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease (clinicaltrials.gov) - Jun 26, 2015
P3, N=20, Recruiting, Sponsor: Amicus Therapeutics
Trial primary completion date: Jun 2015 --> Aug 2016 Trial primary completion date: Dec 2015 --> Oct 2016
- || Trial primary completion date: Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression (clinicaltrials.gov) - Jun 26, 2015
P4, N=242, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Dec 2015 --> Oct 2016 Trial primary completion date: Mar 2016 --> Dec 2016
- ||||||| Galafold (migalastat) / Amicus
Trial completion: Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease (clinicaltrials.gov) - Jun 25, 2015
P3, N=60, Completed, Sponsor: Amicus Therapeutics
Trial primary completion date: Mar 2016 --> Dec 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: IL-7norm: Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=126, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed Recruiting --> Completed | N=55 --> 126 | Trial primary completion date: Dec 2015 --> Jun 2015
- Enrollment open: The CREATE Wellness Study (clinicaltrials.gov) - Jun 12, 2015
P=N/A, N=588, Recruiting, Sponsor: Kaiser Permanente
Recruiting --> Completed | N=55 --> 126 | Trial primary completion date: Dec 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed, Trial primary completion date: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Jun 11, 2015
P3, N=150, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Feb 2015 | Recruiting --> Active, not recruiting
- |||| bococizumab (RN316) / Pfizer
Trial primary completion date: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Jun 11, 2015
P3, N=690, Recruiting, Sponsor: Pfizer
Trial primary completion date: Nov 2015 --> Feb 2015 | Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2015
- Trial primary completion date: Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=10, Active, not recruiting, Sponsor: Tufts University
Trial primary completion date: Jun 2016 --> Jun 2015 Trial primary completion date: Mar 2015 --> Dec 2015
- Trial primary completion date: MK0354 Clinical Efficacy and Tolerability Study (0354-004) (clinicaltrials.gov) - Jun 11, 2015
P2, N=65, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Nov 2006 --> Aug 2006
- Trial primary completion date: Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=20, Recruiting, Sponsor: Tufts University
Trial primary completion date: Nov 2006 --> Aug 2006 Trial primary completion date: Jul 2015 --> Dec 2015
- Trial primary completion date: Effect of Age on Glucose and Lipid Metabolism (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Mar 2015 --> Jun 2015
- Targretin oral (bexarotene oral) / ReXceptor
Trial primary completion date: TgBEX: Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P4, N=15, Recruiting, Sponsor: Rennes University Hospital
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- Kanuma (sebelipase alfa) / AstraZeneca
Trial primary completion date: Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency (clinicaltrials.gov) - Jun 11, 2015
P2, N=8, Active, not recruiting, Sponsor: Synageva BioPharma Corp.
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Dec 2014 --> Mar 2014
- Enrollment change, Trial termination: Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=10, Terminated, Sponsor: Vanderbilt University
Trial primary completion date: Dec 2014 --> Mar 2014 N=20 --> 10 | Recruiting --> Terminated; PI left for another institution
- Enrollment closed: Bergamot and Cardio-Metabolic Risk Factors (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=160, Active, not recruiting, Sponsor: University of Palermo
N=20 --> 10 | Recruiting --> Terminated; PI left for another institution Recruiting --> Active, not recruiting
- tropicamide / Generic mfg.
Enrollment closed, Trial primary completion date: Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=8, Active, not recruiting, Sponsor: Université de Montréal
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- Cerezyme (imiglucerase) / Sanofi
Trial completion, Enrollment change, Trial primary completion date: Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1) (clinicaltrials.gov) - Jun 1, 2015
P=N/A, N=173, Completed, Sponsor: University Research Foundation for Lysosomal Storage Diseases, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 Enrolling by invitation --> Completed | N=250 --> 173 | Trial primary completion date: Sep 2011 --> Dec 2013
- Trial completion: SFLABPASTA: Healthy Effects of an Innovative Probiotic Pasta (clinicaltrials.gov) - May 28, 2015
P=N/A, N=40, Completed, Sponsor: University of Parma
Enrolling by invitation --> Completed | N=250 --> 173 | Trial primary completion date: Sep 2011 --> Dec 2013 Recruiting --> Completed
- Trial completion, Review: Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome (clinicaltrials.gov) - May 27, 2015
P=N/A, N=1, Completed, Sponsor: John Sievenpiper
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: The Medicines Advice Service Evaluation (clinicaltrials.gov) - May 27, 2015
P=N/A, N=677, Completed, Sponsor: University College, London
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Feb 2014 --> Sep 2014
- || Leqvio (inclisiran) / Alnylam, Novartis
Enrollment closed: A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) (clinicaltrials.gov) - May 22, 2015
P1, N=76, Active, not recruiting, Sponsor: Alnylam Pharmaceuticals
Enrolling by invitation --> Completed | Trial primary completion date: Feb 2014 --> Sep 2014 Recruiting --> Active, not recruiting
- pradigastat (LCQ908) / Novartis
Enrollment change, Trial termination: Efficacy of LCQ908 on Cardiovascular Risk (clinicaltrials.gov) - May 21, 2015
P2, N=41, Terminated, Sponsor: Novartis Pharmaceuticals
N=78 --> 41 | Recruiting --> Terminated; The study was terminated based on interim analysis. See detailed description.
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment status, Trial primary completion date: ODYSSEY OLE: Open Label Study of Long Term Safety Evaluation of Alirocumab (clinicaltrials.gov) - May 21, 2015
P3, N=1200, Recruiting, Sponsor: Sanofi
See detailed description. Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2017 --> Jun 2016
- Enrollment closed: Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy (clinicaltrials.gov) - May 19, 2015
P1, N=20, Active, not recruiting, Sponsor: VA Northern California Health Care System
Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2017 --> Jun 2016 Recruiting --> Active, not recruiting
- | CAT-2003 / Astria Therap
Trial completion, Enrollment change: Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia (clinicaltrials.gov) - May 19, 2015
P2, N=13, Completed, Sponsor: Catabasis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=18 --> 13
- ||||||| Trial completion: Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels (clinicaltrials.gov) - May 16, 2015
P3, N=180, Completed, Sponsor: PreEmptive Meds, Pvt. Ltd
Active, not recruiting --> Completed | N=18 --> 13 Recruiting --> Completed
- Trial completion: Study of the Long-term Effects of Exercise on Heath Indicators in Older People (clinicaltrials.gov) - May 16, 2015
P=N/A, N=90, Completed, Sponsor: University of Trás-os-Montes and Alto Douro
Recruiting --> Completed Active, not recruiting --> Completed
- tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute
Enrollment change, Trial termination, Trial primary completion date: Endothelial Hyperpolarization in Humans (clinicaltrials.gov) - May 13, 2015
P2, N=174, Terminated, Sponsor: Emory University
Active, not recruiting --> Completed N=60 --> 174 | Suspended --> Terminated | Trial primary completion date: Jan 2015 --> Jan 2013; Limited clinical staff
- Trial completion: SomaghLipid: The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia (clinicaltrials.gov) - May 13, 2015
P0, N=74, Completed, Sponsor: Shiraz University of Medical Sciences
N=60 --> 174 | Suspended --> Terminated | Trial primary completion date: Jan 2015 --> Jan 2013; Limited clinical staff Recruiting --> Completed
- |||| evacetrapib (LY2484595) / Eli Lilly
Trial primary completion date, Combination therapy: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - May 8, 2015
P3, N=147, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed Trial primary completion date: Sep 2015 --> Dec 2015
- Trial withdrawal: A Screening Study Evaluating Disease Status of Gaucher Type I Patients (clinicaltrials.gov) - May 8, 2015
P=N/A, N=0, Withdrawn, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Sep 2015 --> Dec 2015 Completed --> Withdrawn
- Enrollment closed: Exploration of Immunity in Gaucher Disease (clinicaltrials.gov) - May 8, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: O & O Alpan LLC
Completed --> Withdrawn Recruiting --> Active, not recruiting
- Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Enrollment closed: ECLIPSEIV: An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova (clinicaltrials.gov) - May 6, 2015
P1, N=24, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial primary completion date: Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children (clinicaltrials.gov) - May 5, 2015
P=N/A, N=40, Recruiting, Sponsor: Poudre Valley Health System
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Nov 2015
- Myalept (metreleptin) / Novelion
Trial initiation date: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - May 2, 2015
P=N/A, N=41, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2014 --> Nov 2015 Initiation date: Nov 2008 --> Mar 2009
- || Phase classification, Trial primary completion date: Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression (clinicaltrials.gov) - May 1, 2015
P4, N=242, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Initiation date: Nov 2008 --> Mar 2009 Phase classification: P1 --> P4 | Trial primary completion date: Aug 2016 --> Mar 2016